S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
S&P 500   2,986.20 (-0.39%)
DOW   26,770.20 (-0.95%)
QQQ   191.69 (-0.96%)
AAPL   236.41 (+0.48%)
FB   185.85 (-2.38%)
MSFT   137.41 (-1.63%)
GOOGL   1,244.41 (-0.67%)
AMZN   1,757.51 (-1.68%)
CGC   20.21 (-2.65%)
NVDA   190.49 (-1.96%)
MU   43.47 (-4.46%)
BABA   169.13 (-4.37%)
GE   8.96 (-0.88%)
TSLA   256.95 (-1.92%)
AMD   30.97 (-0.55%)
T   38.47 (+1.75%)
F   9.29 (+1.98%)
ACB   3.68 (-5.40%)
PRI   123.53 (-0.44%)
NFLX   275.30 (-6.15%)
BAC   30.35 (+0.30%)
GILD   64.91 (-0.49%)
DIS   130.89 (-1.12%)
Log in

Jounce Therapeutics Stock Price, News & Analysis (NASDAQ:JNCE)

$3.48
0.00 (0.00 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$3.32
Now: $3.48
$3.52
50-Day Range
$2.81
MA: $3.41
$3.78
52-Week Range
$2.66
Now: $3.48
$7.35
Volume47,448 shs
Average Volume178,432 shs
Market Capitalization$114.78 million
P/E RatioN/A
Dividend YieldN/A
Beta3.49
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.20 million
Book Value$3.18 per share

Profitability

Net Income$-27,380,000.00

Miscellaneous

Employees115
Market Cap$114.78 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.


Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.05. The company had revenue of $17.45 million for the quarter, compared to the consensus estimate of $17.09 million. Jounce Therapeutics had a negative net margin of 46.07% and a negative return on equity of 29.64%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Jounce Therapeutics.

What guidance has Jounce Therapeutics issued on next quarter's earnings?

Jounce Therapeutics updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $148-148 million, compared to the consensus revenue estimate of $85.52 million.

What price target have analysts set for JNCE?

4 equities research analysts have issued 1-year price objectives for Jounce Therapeutics' stock. Their predictions range from $12.00 to $13.00. On average, they anticipate Jounce Therapeutics' stock price to reach $12.50 in the next year. This suggests a possible upside of 259.2% from the stock's current price. View Analyst Price Targets for Jounce Therapeutics.

What is the consensus analysts' recommendation for Jounce Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Has Jounce Therapeutics been receiving favorable news coverage?

Media stories about JNCE stock have trended negative on Friday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Jounce Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Jounce Therapeutics.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 302,000 shares, a decrease of 5.9% from the August 30th total of 320,800 shares. Based on an average trading volume of 170,900 shares, the short-interest ratio is currently 1.8 days. Approximately 2.0% of the shares of the stock are sold short. View Jounce Therapeutics' Current Options Chain.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 60)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Meeder Asset Management Inc. (0.06%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which major investors are buying Jounce Therapeutics stock?

JNCE stock was purchased by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $3.48.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $114.78 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  212 (Thanks for Voting!)
Underperform Votes:  182 (Thanks for Voting!)
Total Votes:  394
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel